By the spring of 1984 Mojsov had developed a number of tools for testing out her hypothesis that GLP-1 (7-37) existed in the gut as well as in small quantities in the pancreas
This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)
If you like the idea of a pill, look up Rybelsus, or if you like the idea of a once-weekly injection, look for Bydureon, Ozempic, or Trulicity
It also supports metabolism, energy levels, and long-term body composition
The condition affects approximately 5% to 10% of the US population, though clinically significant cases requiring treatment are less common